Download PDF
TumorDiagnostik & Therapie 2020; 41(07): 440-444
DOI: 10.1055/a-1155-2733
Schwerpunkt Melanom

Moderne Therapiekonzepte beim metastasierten Melanom

Viktor Alexander Czaika
› Further Information
Also available at
    Permissions and Reprints

Immuntherapie und zielgerichtete Therapie bilden die wesentlichen Säulen in der Behandlung des fortgeschrittenen, metastasierten Melanoms. Dieser Beitrag fasst den aktuellen Stand der Behandlungsoptionen zusammen.

Publication History

Article published online:
31 August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Friedrich S, Kraywinkel K. Epidemiologie des malignen Melanoms in Deutschland. Der Onkologe 2018; 24: 447-452
    CrossrefPubMedGoogle Scholar
  • 2 Garbe C, Keim U, Eigentler TK. et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venerol 2019; DOI: 10.1111/jdv.15322.
    CrossrefPubMedGoogle Scholar
  • 3 Merz R. Melanom – Prävention und Versorgung. TumorDiagn u Ther 2018; 39: 97-99
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Amin MB. (ed). AJCC Cancer Staging Manual. 8. Edition. 2018. ISBN: 978-3-319-40617-6
    Google Scholar
  • 5 Bhatia S, Tykodi SS, Thompson JA. et al. Treatment of metastatic melanoma: an overview. Oncology 2009; 23: 488-496
    PubMedGoogle Scholar
  • 6 Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
    CrossrefPubMedGoogle Scholar
  • 7 Robert C, Long GV, Brady B. et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015; 372: 320-330
    CrossrefPubMedGoogle Scholar
  • 8 Hodi FS, Kluger H, Sznol M. et al Durable, long-term survival in previously treated patients with advancedmelanoma (MEL) who received nivolumab (NIVO) monotherapy in aphase I trial. Cancer Res 2016; 76 (Suppl. 14) Abstract CT001
    CrossrefPubMedGoogle Scholar
  • 9 Schachter J, Ribas A, Long GV. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853-1862
    CrossrefPubMedGoogle Scholar
  • 10 Robert C, Ribas A, Hamid O. et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2016; 34: 9503-9503
    CrossrefPubMedGoogle Scholar
  • 11 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
    CrossrefPubMedGoogle Scholar
  • 12 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356
    CrossrefPubMedGoogle Scholar
  • 13 Terheyden P, Krackhardt A, Eigentler T. Systemische Therapie des Melanoms. Der Stellenwert von Checkpoint-Inhibitoren und die Hemmung von intrazellulärer Signaltransduktion. Dtsch Ärztebl Int 2019; 116: 497-504
    PubMedGoogle Scholar
  • 14 Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol 2015; 1: 380-386
    CrossrefPubMedGoogle Scholar
  • 15 Spagnolo F, Ghiorzo P, Queirolo P. et al. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014; 5: 10206-10221
    CrossrefPubMedGoogle Scholar
  • 16 Long GV, Stroyakovskiy D, Gogas H. et al. Dabrafenib and Trametinib Versus Dabrafenib and Placebo for Val600 BRAF-mutant Melanoma: A Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. Lancet 2015; 386: 444-451
    CrossrefPubMedGoogle Scholar
  • 17 Robert C, Karaszewska B, Schachter J. et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015; 372: 30-39
    CrossrefPubMedGoogle Scholar
  • 18 Ascierto PA, McArthur G, Dréno B. et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 1248-1260
    CrossrefPubMedGoogle Scholar
  • 19 Dummer R, Ascierto PA, Gogas HJ. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19: 603-615
    CrossrefPubMedGoogle Scholar
  • 20 www.awmf.org/leitlinien/detail/ll/032-024OL.html
    PubMed
  • 21 Ribas A, Medina T, Kummar S. et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov 2018; DOI: 10.1158/2159-8290.CD-18-0280.
    CrossrefPubMedGoogle Scholar
  • 22 Papadopoulos KP, Autio KA, Golan T. et al. Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. J Clin Oncol 2019; 37 (Suppl. 15) 9509-9509
    CrossrefPubMedGoogle Scholar
  • 23 Ekladious I, Colson YL, Grinstaff MW. Polymer-drug conjugate therapeutics: advances, insights and prospects. Nature Rev Drug Discov 2018; 18: 273-294
    CrossrefPubMedGoogle Scholar